

# SAR131675

Catalog No: tcsc0970



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

1433953-83-3

**Formula:**

$C_{18}H_{22}N_4O_4$

**Pathway:**

Protein Tyrosine Kinase/RTK

**Target:**

VEGFR

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 28$  mg/mL (78.13 mM)

**Observed Molecular Weight:**

358.39

## Product Description


SAR131675 is a potent and selective **VEGFR3** inhibitor with an **IC<sub>50</sub>** of 23 nM.

IC50 & Target: IC50: 23 nM (VEGFR3)<sup>[1]</sup>

**In Vitro:** AR131675 is highly selective for VEGFR-3 versus 107 receptors, enzymes, ion channels, and 65 kinases. However, it is moderately active on VEGFR-2 with a VEGFR-3/VEGFR-2 ratio of about 10. SAR131675 inhibits VEGFR-3 tyrosine kinase activity and

VEGFR-3 autophosphorylation in HEK cells with  $IC_{50}$  values of 20 and 45 nM, respectively. SAR131675 dose dependently inhibits the proliferation of primary human lymphatic cells, induced by the VEGFR-3 ligands VEGFC and VEGFD, with an  $IC_{50}$  of about 20 nM. SAR131675 has no antiproliferative activity on a panel of 30 tumors and primary cells, further showing its high specificity and indicating that SAR131675 is not a cytotoxic or cytostatic agent<sup>[1]</sup>.

**In Vivo:** SAR131675 is very well tolerated in mice and shows a potent antitumoral effect in several orthotopic and syngenic models, including mammary 4T1 carcinoma and RIP1.Tag2 tumors. Interestingly, it significantly reduces lymph node invasion and lung metastasis, showing its antilymphangiogenic activity *in vivo*. SAR131675 significantly reduces TAM infiltration and aggregation in 4T1 tumors<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!